This week on “The Top Line,” we dig into the 10 biggest potential drug launches of 2025, predicted to rake in a combined $29 billion in annual sales by the end of the decade. More: Looking ahead at the most
read moreIn a lawsuit that received little attention toward the end of last year, Regeneron has taken Sanofi to court over claims that its marketing and development partner violated the terms of a long-standing Dupixent collaboration. Regeneron disclosed the lawsuit in
read more
Partnership aims to leverage cutting-edge technology in clinical trials More: Qureight and Avalyn launch strategic partnership in pulmonary fibrosis Source: News
read more
Designation follows promising preclinical data and FDA clearance More: FDA grants Orphan Drug Designation to Ariceum cancer therapy Source: News
read moreInvivyd has teamed up with professional football coach Jim Harbaugh to tackle COVID-19 complacency. The biotech, which has seen sales of its COVID-19 product fall well short of expectations, is working with Harbaugh to raise awareness of how immunocompromised people
read moreThanks to impressive sales growth across multiple therapeutic areas in 2024, Eli Lilly seems to have assuaged investor concerns that its incretin drugs for diabetes and obesity were reaching a sales plateau. More: Eli Lilly logs massive Q4 revenue jump—but
read more© 1994 - 2025 B.M. Pharmaceuticals